CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study.

Aurélie Benoit,Marie-Hélène B Boies,Nicole Déry,Luciana M Garcia,Mélanie Simard,Mireille Poirier,Robert Delage,Barbara Lortal Canguilhem,Catherine Doyle,Jean-François Larouche,Félix Couture,Christopher Lemieux

Clinical lymphoma, myeloma & leukemia

引用 0|浏览0

暂无评分

摘要

The poor response rate at 3 months after infusion in our cohort was influenced mainly by bulky disease. Further studies are needed to better characterize the loss of efficacy of CAR T-cells because the majority of patients will relapse over time.

查看译文

关键词

Axicabtagene ciloleucel,Cellular therapy,Efficacy,Tisagenlecleucel,Tolerance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要